
Clearmind Medicine Inc.
CMND·NASDAQ
Last updated as of 2026-03-20 10:41 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
CMND stock price change
On the last trading day, CMND stock closed at 0.68 USD, with a price change of -9.80% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreCMND key data
Previous close0.68 USD
Market cap1.41M USD
Volume544.14K
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-24.14 USD
Net income (FY)−3.86M USD
Revenue (FY)0.00 USD
Next report date-
EPS estimate-
Revenue estimate-
Shares float58.35K
Beta (1Y)0.89

Clearmind Medicine Inc. overview
Clearmind Medicine, Inc. is a psychedelic pharmaceutical biotech company. It focuses on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize it as regulated medicines, foods, or supplements. The company was founded on July 18, 2017 and is headquartered in Vancouver, Canada.
Sector
Non-energy minerals
Industry
Other Metals/Minerals
CEO
Adi Zuloff-Shani
Headquarters
Vancouver
Website
clearmindmedicine.com
Founded
2017
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-
CMND stock price forecast
According to technical indicators for CMND stock, the price is likely to fluctuate within the range of 0.70–0.77 USD over the next week. Market analysts predict that the price of CMND stock will likely fluctuate within the range of 0.63–0.85 USD over the next months.
Based on 1-year price forecasts from 49 analysts, the highest estimate is 3.39 USD, while the lowest estimate is 1.23 USD.
For more information, please see the
CMND stock price forecast
page.
Latest CMND stock news
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Finviz2026-03-04 12:33:40
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Finviz2026-03-04 12:33:40
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-10 13:03:57
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
Finviz2026-03-11 13:09:42
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-12 12:00:47
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Finviz2026-03-13 11:48:53
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
Finviz2026-03-16 12:21:46
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
Finviz2026-03-17 13:18:09
Clearmind Medicine announced that its Phase I/Iia clinical trial of Cmnd-100 for alcohol use disorder is progressing smoothly at research centers across the United States.
老虎证券2026-03-19 13:46:03
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Finviz2026-03-04 12:33:40
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Finviz2026-03-04 12:33:40
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-10 13:03:57
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
Finviz2026-03-11 13:09:42
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Finviz2026-03-12 12:00:47
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Finviz2026-03-13 11:48:53





